Background
Acute lower extremity ischaemia (ALEI) is a vascular emergency with a mortality rate of 15-20%.2 Treatment is multi-faceted and is typically aimed at restoring blood flow and can be performed surgically, endovascularly, or through a hybrid method.3
Method
Single-centre retrospective review of 27 ALEI patients treated with the JETi™ System. 89% of patients met criteria for Rutherford IIa or IIb classification. Patients were treated endovascularly or through a hybrid surgical approach. Adjunctive treatment included angioplasty, stenting and open thrombectomy.
Endpoints
Removal of over 50% of clot burden from target artery, restoration of inline flow. Indications, limb salvage, and major adverse events were reviewed.
Despite a challenging patient population, target thrombus was successfully removed in 85% of JETi™ cases with zero patient deaths at 30 days.
| Target Thrombus Successfully Removed | JETi™ |
|---|---|
| JETi™ Alone | 26% (7/27) |
| JETi™ + Adjunctive Procedures* | 59% (16/27) |
| Overall (includes JETi™ Alone and JETi™ + Adjunctive Procedures) | 85% (23/27) |
*Angioplasty, stenting, open thrombectomy.
JETi™, alone or with adjunctive procedures, was successful in removing target thrombus in 85% of cases.
Zero deaths and only four major limb amputations were reported at 30-days in this challenging population.
JETi™ is a safe and efficacious tool for the treatment of acute lower extremity ischaemia (ALEI).
MAT-2409397 v1.0
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions
MAT-2105201 v1.0
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions
MAT-2105201 v1.0
